Respiratory / Chronic Obstructive Pulmonary Disease
Indication
Chronic Obstructive Pulmonary Disease
Assets addressing this indication.
Total attributable cost
$48.0B
$4,322/patient
Drug spend
$20.9B
$1,887/patient
44% of total cost is drugs
All severities, diagnosed (2022 estimate) · US